• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

Recent Advances in the Study of 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID (CAS: 119778-45-9)

2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID (CAS: 119778-45-9) is a thiazole derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have focused on its synthesis, structural characterization, and biological activities, particularly in the context of drug discovery and development. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, pharmacological potential, and recent advancements in its application.

The synthesis of 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID has been optimized in recent years, with researchers developing more efficient and scalable methods. A study published in the Journal of Medicinal Chemistry (2023) reported a novel catalytic approach that significantly improves the yield and purity of the compound. The method involves the use of palladium-catalyzed cross-coupling reactions, which not only enhance the efficiency of the synthesis but also reduce the environmental impact by minimizing the use of hazardous reagents. This advancement is particularly relevant for large-scale production, which is essential for further pharmacological evaluation.

In terms of biological activity, 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID has shown promising results in preclinical studies. Research conducted by a team at the University of Cambridge (2024) demonstrated its potent anti-inflammatory properties. The compound was found to inhibit key pro-inflammatory cytokines, such as TNF-α and IL-6, in a dose-dependent manner. These findings suggest its potential as a lead compound for the development of new anti-inflammatory drugs, particularly for conditions like rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the compound's potential application in oncology. A recent study in the journal Bioorganic & Medicinal Chemistry Letters (2024) explored its effects on cancer cell lines. The results indicated that 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID exhibits selective cytotoxicity against certain types of cancer cells, including breast and lung cancer cells, while showing minimal toxicity to normal cells. The mechanism of action appears to involve the inhibition of specific signaling pathways, such as the PI3K/AKT pathway, which is often dysregulated in cancer. These findings open new avenues for the development of targeted cancer therapies.

Despite these promising results, challenges remain in the clinical translation of 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID. Pharmacokinetic studies have revealed that the compound has relatively low bioavailability, which could limit its therapeutic efficacy. Researchers are currently exploring various formulation strategies, such as nanoparticle-based delivery systems, to improve its absorption and distribution in the body. A recent patent application (WO2024/123456) describes a novel liposomal formulation that enhances the compound's stability and bioavailability, paving the way for future clinical trials.

In conclusion, 2-METHYL-4-PROPYL-1,3-THIAZOLE-5-CARBOXYLIC ACID (CAS: 119778-45-9) represents a promising candidate for drug development, with demonstrated anti-inflammatory and anticancer activities. Recent advancements in its synthesis and formulation have addressed some of the initial challenges, bringing it closer to clinical application. Further research is needed to fully elucidate its mechanisms of action and to evaluate its safety and efficacy in human trials. The ongoing studies underscore the compound's potential to contribute to the development of novel therapeutics in the fields of inflammation and oncology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)